Intensity modulated radiation therapy (IMRT) is receiving increasing attention in gynecologic malignancies. Dosimetric studies have demonstrated that IMRT reduces the volume of normal tissues irradiated compared to conventional techniques. Moreover, recent outcome studies have suggested that IMRT is associated with less acute and chronic toxicity. A concern, however, is that no standards exist on how gynecologic IMRT should be performed. To develop guidelines, the Gynecologic IMRT Working Group was formed comprised of investigators from the United States, Canada, Asia and Europe. Recently, members were sent a survey on intensity modulated pelvic RT (IM-PRT). The 45-question survey focused on the use of adjuvant IM-PRT in endometrial and cervical cancer. It did not address IMRT in women with an intact uterus or more comprehensive fields. The survey consisted of 6 sections: patient selection, equipment, simulation, target delineation, planning and delivery. Members were asked to give their recommendations. Twenty-seven members (18 USA, 4 Europe, 3 Asia, 2 Canada) completed the survey. Number of sections completed varied by gynecologic IMRT experience. All respondents were academic physicians (median years in practice, 13). Most (89%) were IMRT-users; 63% had treated a gynecology patient with IMRT. Most common contraindications to gynecologic IMRT cited were obesity and poor cooperation. Most respondents (78%) recommended inverse planning. All commercial planning systems were considered acceptable. Recommended positioning was supine (46%), prone (15%) or either (39%). Most (81%) recommended customized immobilization. All recommended thin (3–5 mm) planning CT slices and 88% recommended contrast at simulation, primarily intravenous, rectal, and oral contrast. Most (80%) recommended a vaginal marker. All respondents recommended contouring of the bladder, rectum, and small bowel as avoidance structures. Other tissues contoured included the femoral heads (84%), bone marrow (38%), sigmoid (4%), vulva (2%), and sacrum (2%). Most respondents (72%) recommended inclusion of the vagina, parametria, presacral region, and external, internal, and common iliac lymph nodes in the clinical target volume (CTV). Fifty-two percent, however, recommended different CTVs for cervical and endometrial cancer, the main difference being the exclusion of the presacral region in endometrial cancer. Sixteen percent did not recommend inclusion of the common iliacs in either disease. Additional radiographic studies (predominantly PET and MR) were recommended by 46% to aid in CTV delineation. All recommended a CTV-to-PTV expansion, primarily 5–10 mm. Eighteen percent recommended expansion of the normal tissues. Recommended beam configurations were: 5–9 beams (94%), equally-spaced angles (70%) and coplanar beams (88%). Sixteen respondents provided detailed input planning parameters and acceptance criteria for both PTV and normal tissue dose-volume histograms. Minimum and maximum PTV doses of 95% and 105–110% of the prescription dose were recommended by 62% and 71%, respectively. All recommended quality assurance prior to and throughout treatment. This is the first survey of the application of IMRT to gynecologic tumors and provides insight into its use at a wide variety of centers. While differences in recommended practice were observed, considerable agreement exists between investigators. These results will form the basis of an upcoming consensus statement on adjuvant IM-PRT from the Gynecologic IMRT Working Group. Current work is focused on developing guidelines for target delineation
Read full abstract